卵巢癌化疗患者紫杉醇血药浓度监测的临床价值

发布时间：2018-06-07 02:51

  本文选题：卵巢癌 + 紫杉醇　； 参考：《肿瘤防治研究》2017年04期

【摘要】：目的研究卵巢癌患者化疗后,紫杉醇(PTX)血药浓度与疗效及不良反应的相关性。方法75例卵巢癌患者接受PT方案(紫杉醇+卡铂)一线化疗。于每周期PTX静脉输注开始后(24±6)h采集静脉血2次,采用胶乳免疫比浊法检测PTX浓度。根据PTX血药浓度的平均值,将75例患者分为≤25 h组、(26~30)h组和≥31 h组,回顾性分析PTX血药浓度与疗效及与不良反应间的相关性。结果≤25 h组、(26~30)h组、≥31 h组PTX血药浓度分别为(22.54±2.04)h、(28.62±1.87)h、(33.01±2.84)h,差异有统计学意义(P0.05)。随着PTX血药浓度的升高,化疗的不良反应发生率增多,程度加强(P0.05)。(26~30)h组的有效率(31.25%)高于≤25 h组(20%)(P=0.02),与≥31 h组有效率(33.33%)相比差异无统计学意义(P=0.96)。结论卵巢癌采用紫杉醇PTX血药浓度在(26~30)h的患者疗效好,且不良反应稍低。
[Abstract]:Objective to study the correlation between plasma concentration of paclitaxel PTX and therapeutic effect and adverse reaction after chemotherapy in patients with ovarian cancer. Methods 75 patients with ovarian cancer were treated with PT regimen (paclitaxel carboplatin). Venous blood was collected twice at 24 卤6 hours after each cycle of PTX infusion, and the concentration of PTX was detected by latex immunoturbidimetry. According to the average blood drug concentration of PTX, 75 patients were divided into two groups: group 鈮，

本文编号：1989415